Welcome to our dedicated page for Plandai Biotechnology news (Ticker: PLPL), a resource for investors and traders seeking the latest updates and insights on Plandai Biotechnology stock.
Plandai Biotechnology, Inc. (PLPL) specializes in advanced botanical extraction technologies for the global nutraceutical and pharmaceutical markets. This page serves as the definitive source for verified corporate disclosures, including regulatory filings, product development milestones, and strategic business updates.
Investors and industry professionals will find timely updates on the company's Phytofare® extract line development, agricultural operations in South Africa, and material corporate actions. Recent coverage includes the rescission of the Good Salt LLC agreement following shareholder approval, demonstrating our commitment to transparent reporting of significant business developments.
The news archive maintains comprehensive records of financial disclosures, partnership announcements, and operational updates from Plandai's dual focus areas: proprietary extract development and sustainable agricultural production. Key areas of coverage include clinical research progress, intellectual property updates, and production capacity expansions.
Bookmark this page for direct access to primary source materials and official statements regarding Plandai's innovative work in catechin-rich formulations and agricultural asset management. Check regularly for updates on regulatory submissions and global market expansion initiatives.
Plandai Biotechnology (OTC PINK:PLPL) announced its asset acquisition agreement with EV Hotel Corp, aiming to innovate the hospitality industry with the smart hotel concept. This platform integrates technology, automation, IoT, crypto, and NFTs to enhance guest experiences and operational efficiency. The acquisition will involve a reverse stock split of 100:1 and controls changing hands with the issuance of common and Series 'A' Preferred stock. EV Hotel's first franchise is set to transform a historic Travelodge in Phoenix into a smart hotel, projected to open in 2023.
Plandai Biotechnology (OTC PINK: PLPL) announced a non-binding letter of intent with EV Hotel Corp. to merge, as part of its strategy to enhance shareholder value. EV Hotel is recognized for its innovative hospitality platform, defining a new standard in hotel management through automation, IoT, and crypto integration. Their franchise model has commenced with a conversion of a Travelodge in Arizona into a smart hotel. Plandai is finalizing an independent two-year audit, a critical step towards completing this merger, aimed at driving growth and operational excellence.
Plandai Biotechnology has terminated its non-binding letter of intent with Ms. Jessie Chiang for licensing the Puriblood Leukocyte Reduction Blood Filtration System. This agreement aimed to secure exclusive rights for North, Central, and South America but would have led to Ms. Chiang acquiring a controlling interest in Plandai. The Company is exploring new strategic opportunities to enhance shareholder value and has engaged Hudgens, CPAs for an independent financial audit for fiscal years 2021 and 2022, with plans to file a registration statement following the audit's completion.
Plandai Biotechnology Inc. (OTC PINK:PLPL) announced the cancellation of approximately $200,000 in civil penalties and interest by the U.S. SEC related to a previous enforcement action. CEO Tad Mailander expressed optimism about resolving legacy financial issues, including the settlement of $6.9 million in outstanding notes payable. The Company is pursuing a licensing deal with Puri Blood and planning a two-year audit to file a registration statement with the SEC, aiming for enhanced future opportunities.
Plandai Biotechnology Inc. (OTC PINK:PLPL) announced a non-binding letter of intent to license the Puriblood Leukocyte Reduction Blood Filtration System, enhancing its focus on blood purification technology. The deal grants exclusive rights for North, Central, and South America for 30 years, pending due diligence. The system effectively reduces leukocytes in blood, crucial for transfusion safety, and is patented in key markets. Jessie Chiang is set to acquire a controlling interest and take over as CEO after the agreement's closure. Success in this venture could align with strong market growth projections.
FAQ
What is the current stock price of Plandai Biotechnology (PLPL)?
What is the market cap of Plandai Biotechnology (PLPL)?
